Clinical Data Maze tumbles despite positive data for kidney disease drug BioPharma DiveInvestors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.Clinical DataRare DiseaseRead full story pharminent March 25, 2026 (Last updated: March 26, 2026) BioPharma Dive Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease. Clinical DataRare DiseaseRead full story Post navigation Previous: Beam posts positive data on base editing treatment for AATDNext: Wave crashes on obesity drug update; Kodiak’s reboot pays dividends Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026